From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2023 Mar 29

PMID 36979861

Authors

Andrea Boccatonda

Lorenzo Andreetto

Damiano DArdes

Giulio Cocco

Ilaria Rossi

Susanna Vicari

Cosima Schiavone

Francesco Cipollone

Maria Teresa Guagnano

Affiliations

Soon will be listed here.

Abstract

Non-alcoholic fatty liver disease (NAFLD) is defined as a chronic liver disease characterized by excessive fat accumulation in the liver without another obvious cause (no excessive alcohol consumption, hepatotoxic medications, toxins, viral infections, genetic hepatic diseases), therefore it is an exclusion diagnosis. The term NAFLD literally refers to non-alcohol related hepatopathy and does not adequately correlate with metabolic dysfunction and related cardiovascular risks. Therefore, researchers and scientific societies have moved towards changing the terminology. The novel nomenclature for a metabolic-associated fatty liver disease (MAFLD) has been proposed in 2020 by a group of experts to overcome the issues related to the old terminology. The diagnosis of MAFLD is based on the presence of hepatic steatosis and at least one between these three conditions: type 2 diabetes mellitus (T2DM), obesity or metabolic dysregulation. MAFLD has been shown to be an independent risk factor for cardiovascular diseases and atherosclerosis. It is better related to the main risk factors for atherosclerosis and cardiovascular diseases than NAFLD, such as dyslipidemia, T2DM and hypertension. The aim of this review is to highlight the reasons why the term NAFLD is moving to the term MAFLD, what are the conceptual basis of this choice and its clinical implications, particularly in the cardiovascular field.

Citing Articles

Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.

Devasia A, Ramasamy A, Leo C Int J Mol Sci. 2025; 26(4).

PMID: 40004240 PMC: 11855529. DOI: 10.3390/ijms26041778.

Comparative application of MAFLD and MASLD diagnostic criteria on NAFLD patients: insights from a single-center cohort.

Elsabaawy M, Naguib M, Abuamer A, Shaban A Clin Exp Med. 2025; 25(1):36.

PMID: 39808219 PMC: 11732950. DOI: 10.1007/s10238-024-01553-3.

Circulating irisin levels in patients with MAFLD: an updated systematic review and meta-analysis.

Shen C, Wu K, Ke Y, Zhang Q, Chen S, Li Q Front Endocrinol (Lausanne). 2025; 15:1464951.

PMID: 39741878 PMC: 11686449. DOI: 10.3389/fendo.2024.1464951.

Impact of Liver Disease on Use of Muscle Relaxants in Anesthesia: A Comprehensive Review.

Radkowski P, Szewczyk M, Leczycka A, Kowalczyk K, Keska M, Stompor T Med Sci Monit. 2025; 31:e945822.

PMID: 39741402 PMC: 11702445. DOI: 10.12659/MSM.945822.

Impact of Dietary Niacin on Metabolic Dysfunction-Associated Steatotic Liver Disease in Mediterranean Subjects: A Population-Based Study.

Antentas M, Rojo-Lopez M, Vendrell P, Granado-Casas M, Genua I, Fernandez-Camins B Nutrients. 2024; 16(23).

PMID: 39683571 PMC: 11644089. DOI: 10.3390/nu16234178.

References

Angulo P . Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346(16):1221-31. DOI: 10.1056/NEJMra011775. View

Bessho R, Kashiwagi K, Ikura A, Yamataka K, Inaishi J, Takaishi H . A significant risk of metabolic dysfunction-associated fatty liver disease plus diabetes on subclinical atherosclerosis. PLoS One. 2022; 17(5):e0269265. PMC: 9154100. DOI: 10.1371/journal.pone.0269265. View

Boccatonda A, Tripaldi R, Davi G, Santilli F . Oxidative Stress Modulation Through Habitual Physical Activity. Curr Pharm Des. 2016; 22(24):3648-80. DOI: 10.2174/1381612822666160413123806. View

Elagizi A, Kachur S, Lavie C, Carbone S, Pandey A, Ortega F . An Overview and Update on Obesity and the Obesity Paradox in Cardiovascular Diseases. Prog Cardiovasc Dis. 2018; 61(2):142-150. DOI: 10.1016/j.pcad.2018.07.003. View

Postic C, Girard J . Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008; 118(3):829-38. PMC: 2254980. DOI: 10.1172/JCI34275. View

Meyersohn N, Mayrhofer T, Corey K, Bittner D, Staziaki P, Szilveszter B . Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. Clin Gastroenterol Hepatol. 2020; 19(7):1480-1488.e14. PMC: 7855524. DOI: 10.1016/j.cgh.2020.07.030. View

Wijarnpreecha K, Panjawatanan P, Kroner P, Cheungpasitporn W, Ungprasert P . Association between cardiac conduction defect and nonalcoholic fatty liver disease: a systematic review and meta-analysis. Ann Gastroenterol. 2020; 33(6):661-666. PMC: 7599342. DOI: 10.20524/aog.2020.0535. View

Petit J, Cercueil J, Loffroy R, Denimal D, Bouillet B, Fourmont C . Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study. J Clin Endocrinol Metab. 2016; 102(2):407-415. DOI: 10.1210/jc.2016-2775. View

Alkagiet S, Papagiannis A, Tziomalos K . Associations between nonalcoholic fatty liver disease and ischemic stroke. World J Hepatol. 2018; 10(7):474-478. PMC: 6068844. DOI: 10.4254/wjh.v10.i7.474. View

10.

Santos R, Valenti L, Romeo S . Does nonalcoholic fatty liver disease cause cardiovascular disease? Current knowledge and gaps. Atherosclerosis. 2019; 282:110-120. DOI: 10.1016/j.atherosclerosis.2019.01.029. View

11.

Sone H, Mizuno S, Fujii H, Yoshimura Y, Yamasaki Y, Ishibashi S . Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in asian diabetic patients? Analysis from the Japan Diabetes Complications Study. Diabetes Care. 2005; 28(6):1463-71. DOI: 10.2337/diacare.28.6.1463. View

12.

Vadini F, Simeone P, Boccatonda A, Guagnano M, Liani R, Tripaldi R . Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study. Int J Obes (Lond). 2020; 44(6):1254-1263. DOI: 10.1038/s41366-020-0535-5. View

13.

Lessiani G, Santilli F, Boccatonda A, Iodice P, Liani R, Tripaldi R . Arterial stiffness and sedentary lifestyle: Role of oxidative stress. Vascul Pharmacol. 2015; 79:1-5. DOI: 10.1016/j.vph.2015.05.017. View

14.

Niederseer D, Wernly B, Aigner E, Stickel F, Datz C . NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations. J Clin Med. 2021; 10(3). PMC: 7865665. DOI: 10.3390/jcm10030467. View

15.

Loria P, Lonardo A, Carulli N . Should nonalcoholic fatty liver disease be renamed?. Dig Dis. 2005; 23(1):72-82. DOI: 10.1159/000084728. View

16.

ONeil P, Birkenfeld A, McGowan B, Mosenzon O, Pedersen S, Wharton S . Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018; 392(10148):637-649. DOI: 10.1016/S0140-6736(18)31773-2. View

17.

Gastaldelli A . Is it necessary to target lipid metabolism in different organs for effective treatment of NASH?-the results of the Pan-PPAR Lanifibranor trial. Hepatobiliary Surg Nutr. 2022; 11(3):481-484. PMC: 9186198. DOI: 10.21037/hbsn-21-569. View

18.

Liu J, Lv H, Wang J, Zhu Q, Chen G, Jiang Y . Blood pressure stratification for predicting liver fibrosis risk in metabolic dysfunction associated fatty liver disease. Ann Hepatol. 2022; 28(2):100892. DOI: 10.1016/j.aohep.2022.100892. View

19.

Sven M F, Pierre B, Manal F A, Quentin M A, Elisabetta B, Vlad R . A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study. Contemp Clin Trials. 2020; 98:106170. DOI: 10.1016/j.cct.2020.106170. View

20.

Tana C, Ballestri S, Ricci F, Di Vincenzo A, Ticinesi A, Gallina S . Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int J Environ Res Public Health. 2019; 16(17). PMC: 6747357. DOI: 10.3390/ijerph16173104. View